Biocon’s U.S. Facility Clears FDA GMP Inspection with One Observation

Biocon Limited has successfully completed a U.S. FDA Good Manufacturing Practice (GMP) inspection at its newly inaugurated Cranbury, New Jersey facility, with only one observation raised. The company has committed to addressing the observation within the stipulated time and expects no disruption to operations. The Cranbury site is a strategic hub for Biocon’s U.S. expansion, aimed at enhancing supply chain efficiency and scaling up manufacturing capacity. Some products are already commissioned, with more launches planned. This facility strengthens Biocon’s ability to deliver affordable, high-quality biopharmaceuticals to U.S. patients and reinforces its vertically integrated global supply chain. In a regulatory filing, Biocon highlighted that the site enables faster access to its product portfolio. The clean inspection outcome marks a key milestone in establishing local manufacturing presence in the U.S., boosting credibility and long-term market reach in one of the world’s most regulated and valuable pharmaceutical markets.